Maze Therapeutics, Inc. (MAZE) Stock Analysis
Healthcare · Biotechnology · NasdaqGM
Maze Therapeutics, Inc. (MAZE) posted $0 in revenue for fiscal 2025 (down 100.0% year over year), with a net loss of $131.12M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Maze Therapeutics, Inc.
Maze Therapeutics, Inc. has grown revenue from $0 to $0 over the last 4 fiscal years. The most recent year was down 100%.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Maze Therapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Maze Therapeutics, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $167.50M | $0 |
| Gross profit | — | — | — | — |
| Net income | $-114.94M | $-100.42M | $52.23M | $-131.12M |
| Net margin | — | — | 31.2% | — |
Source: Maze Therapeutics, Inc. SEC filings (10-K).
Maze Therapeutics, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 12.7% over 3 years (43.8M → 49.3M) — existing holders' stakes are being diluted.
Explore 4 years of Maze Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MAZE in your portfolio →
Maze Therapeutics, Inc. financial history by metric
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Maze Therapeutics, Inc. — frequently asked questions
What is Maze Therapeutics, Inc.'s revenue?
Maze Therapeutics, Inc. (MAZE) reported revenue of $0 for fiscal year 2025, down 100.0% from the prior year, according to its SEC filings.
Is Maze Therapeutics, Inc. profitable?
No — MAZE reported a net loss of $-131.12M in fiscal 2025.
What is MAZE's P/E ratio?
Maze Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Maze Therapeutics, Inc. have?
As of fiscal year 2025, MAZE carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Maze Therapeutics, Inc.'s market cap?
Maze Therapeutics, Inc. (MAZE) has a market capitalization of about $1.36B, based on the latest data in our nightly-refreshed cache.
When does Maze Therapeutics, Inc.'s fiscal year end?
MAZE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Maze Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.